US Senate aides will meet with Novo Nordisk executives on Tuesday to discuss the consequences of its decision to stop selling one of its long-acting insulins in the country. In April, lawmakers wrote to the company expressing alarm over its decision to permanently discontinue Levemir at the end of 2024.